• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

帕博利珠单抗与维布妥昔单抗联合治疗在多次治疗的复发/难治性霍奇金淋巴瘤中的长期缓解

Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin's Lymphoma.

作者信息

Yu Tsung-Ying, Dai Ming-Shen

机构信息

Division of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

出版信息

J Hematol. 2020 Apr;9(1-2):30-32. doi: 10.14740/jh596. Epub 2020 Apr 23.

DOI:10.14740/jh596
PMID:32362983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7188374/
Abstract

Hodgkin's lymphoma (HL) is usually sensitive and curative to multi-agent chemotherapy, but may become refractory disease in a subset of relapsed patients. Recent novel agents, brentuximab-vedotin (BV) and immune checkpoint inhibitors have significantly improve the treatment outcome. We report the outcome by combination of BV with pembrolizumab in a patient with a relapsed/refractory HL in a remarkable and durable response, even previously failed to multiple lines of chemotherapy, or brentuximab-vedotin/pembrolizumab monotherapy. Further investigation of immunotherapy combination in relapsed/refractory HL is needed.

摘要

霍奇金淋巴瘤（HL）通常对多药化疗敏感且可治愈，但在一部分复发患者中可能会成为难治性疾病。近期的新型药物，如本妥昔单抗（BV）和免疫检查点抑制剂，显著改善了治疗效果。我们报告了1例复发/难治性HL患者采用BV联合帕博利珠单抗治疗的结果，该患者取得了显著且持久的缓解，即便此前对多线化疗、或本妥昔单抗/帕博利珠单抗单药治疗均无效。复发/难治性HL免疫治疗联合方案仍需进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f2a/7188374/eaa82208abbf/jh-09-030-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f2a/7188374/eaa82208abbf/jh-09-030-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f2a/7188374/eaa82208abbf/jh-09-030-g001.jpg

相似文献

1
Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin's Lymphoma.帕博利珠单抗与维布妥昔单抗联合治疗在多次治疗的复发/难治性霍奇金淋巴瘤中的长期缓解
J Hematol. 2020 Apr;9(1-2):30-32. doi: 10.14740/jh596. Epub 2020 Apr 23.
2
Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison.帕博利珠单抗对比在接受维布妥昔单抗治疗后进展的复发难治性经典型霍奇金淋巴瘤的标准治疗：一项间接治疗比较
Expert Rev Hematol. 2018 Jun;11(6):503-511. doi: 10.1080/17474086.2018.1475226. Epub 2018 May 23.
3
Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.复发或难治性霍奇金淋巴瘤患者接受本妥昔单抗治疗失败后单药苯达莫司汀的安全性和有效性：27例患者的经验
Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):404-8. doi: 10.1016/j.clml.2015.02.023. Epub 2015 Mar 5.
4
Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.在人霍奇金淋巴瘤小鼠模型中，本妥昔单抗联合鲁索替尼和/或纳维托克司的增强疗效。
Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):1624-9. doi: 10.1073/pnas.1524668113. Epub 2016 Jan 25.
5
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.本妥昔单抗维迪昔联合 ABVD 或 AVD 方案用于治疗初诊霍奇金淋巴瘤患者的 1 期、开放标签、剂量递增研究。
Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15.
6
A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.在干细胞移植前后，对经过大量治疗的难治性或复发性儿童霍奇金淋巴瘤患者采用维布妥昔单抗进行靶向挽救治疗。
Turk J Pediatr. 2019;61(5):671-676. doi: 10.24953/turkjped.2019.05.005.
7
The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors.在用维布妥昔单抗和/或免疫检查点抑制剂治疗后，放射治疗在难治性霍奇金淋巴瘤患者中的作用。
J Natl Cancer Cent. 2023 Nov 10;4(1):86-92. doi: 10.1016/j.jncc.2023.11.001. eCollection 2024 Mar.
8
Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin's lymphoma: a United States payer perspective.帕博利珠单抗对比维布妥昔单抗治疗复发或难治性经典型霍奇金淋巴瘤的成本效益：美国医保支付方视角
J Med Econ. 2018 Nov 13;22(1):16-25. doi: 10.1080/13696998.2018.1534738.
9
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.维布妥昔单抗治疗儿童复发或难治性霍奇金淋巴瘤及间变性大细胞淋巴瘤：一项多中心、开放标签的1/2期研究。
Lancet Haematol. 2018 Oct;5(10):e450-e461. doi: 10.1016/S2352-3026(18)30153-4.
10
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.本妥昔单抗维泊妥珠单抗作为自体造血干细胞移植后巩固治疗在有复发或进展风险的霍奇金淋巴瘤患者中的应用（AETHERA）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19.

引用本文的文献

1
Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.抗 CD30 抗体药物偶联物治疗淋巴瘤：现有知识、尚存争议和未来展望。
Ann Hematol. 2023 Jan;102(1):13-29. doi: 10.1007/s00277-022-05054-9. Epub 2022 Dec 13.
2
Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review.本妥昔单抗和纳武单抗治疗难治性或复发性霍奇金淋巴瘤的疗效：一项系统评价。
Cureus. 2022 Mar 24;14(3):e23452. doi: 10.7759/cureus.23452. eCollection 2022 Mar.
3
Classical Hodgkin's lymphoma with cutaneous involvement in an adolescent male: A case study.

本文引用的文献

1
Where does PD-1 blockade fit in HL therapy?PD-1 阻断疗法在 HL 治疗中的地位如何？
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):213-220. doi: 10.1182/asheducation-2018.1.213.
2
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.抗程序性死亡蛋白1（PD-1）治疗失败后，化疗或化疗联合抗PD-1疗法用于复发难治性霍奇金淋巴瘤的疗效：来自Lysa中心的系列研究
Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154.
3
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
青少年男性皮肤受累的经典霍奇金淋巴瘤：病例研究。
Cancer Rep (Hoboken). 2022 Feb;5(2):e1473. doi: 10.1002/cnr2.1473. Epub 2021 Jun 5.
本妥昔单抗维迪西妥单抗联合苯达莫司汀：复发或难治性霍奇金淋巴瘤的高效一线挽救治疗方案。
Blood. 2018 Jul 5;132(1):40-48. doi: 10.1182/blood-2017-11-815183. Epub 2018 Apr 27.
4
Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.CD30 和 PD-1 靶向治疗经典型霍奇金淋巴瘤的进展。
J Hematol Oncol. 2018 Apr 23;11(1):57. doi: 10.1186/s13045-018-0601-9.
5
[Hodgkin lymphoma: Current and future therapeutic strategies].[霍奇金淋巴瘤：当前及未来的治疗策略]
Bull Cancer. 2018 Jan;105(1):81-98. doi: 10.1016/j.bulcan.2017.11.008. Epub 2017 Dec 27.
6
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.本妥昔单抗维迪西妥单抗联合苯达莫司汀治疗复发或难治性霍奇金淋巴瘤的国际多中心单臂 1/2 期临床试验。
Lancet Oncol. 2018 Feb;19(2):257-266. doi: 10.1016/S1470-2045(17)30912-9. Epub 2017 Dec 21.
7
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.帕博利珠单抗治疗复发/难治性经典型霍奇金淋巴瘤的疗效和安全性II期研究。
J Clin Oncol. 2017 Jul 1;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316. Epub 2017 Apr 25.
8
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.复发或难治性霍奇金淋巴瘤患者使用维布妥昔单抗的5年生存率和疗效持久性结果
Blood. 2016 Sep 22;128(12):1562-6. doi: 10.1182/blood-2016-02-699850. Epub 2016 Jul 18.
9
Cancer treatment and survivorship statistics, 2016.癌症治疗和生存统计，2016 年。
CA Cancer J Clin. 2016 Jul;66(4):271-89. doi: 10.3322/caac.21349. Epub 2016 Jun 2.
10
Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies.用于治疗复发或难治性恶性淋巴瘤的本妥昔单抗：前瞻性研究的系统评价和荟萃分析结果
Drug Des Devel Ther. 2015 Apr 21;9:2277-83. doi: 10.2147/DDDT.S83592. eCollection 2015.